PTC Therapeutics (NASDAQ:PTCT) Insider Sells $98,419.05 in Stock

09 Jan 2026, 00:52 by Mitch Edgeman · The Markets Daily

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total transaction of $98,419.05. Following the completion of the sale, the insider directly owned 117,103 shares of the company’s stock, valued at approximately $9,011,075.85. This trade represents a 1.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Neil Gregory Almstead also recently made the following trade(s):

On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total transaction of $4,028.96.
On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $79,494.48.
On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $4,155.30.
On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The stock was sold at an average price of $80.18, for a total value of $2,852,162.96.
On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The stock was sold at an average price of $83.44, for a total value of $6,001,672.32.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT traded down $0.39 during midday trading on Thursday, hitting $76.85. 1,625,361 shares of the stock traded hands, compared to its average volume of 1,684,365. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The business has a 50 day moving average price of $76.26 and a two-hundred day moving average price of $62.43. The company has a market cap of $6.17 billion, a PE ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. PTC Therapeutics’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.39) EPS. As a group, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC grew its position in shares of PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares during the period. Optiver Holding B.V. raised its holdings in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares during the period. Comerica Bank lifted its stake in PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares during the last quarter. IFP Advisors Inc grew its holdings in PTC Therapeutics by 68.1% during the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 310 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in PTC Therapeutics by 42.1% in the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 295 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Citigroup increased their price objective on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and raised their target price for the company from $82.00 to $91.00 in a report on Monday, December 1st. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $90.00 price target on shares of PTC Therapeutics in a research report on Thursday. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $77.27.

Read Our Latest Stock Analysis on PTC Therapeutics

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.